Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 3

Results: 17

Some design considerations incorporating early futility for single‐arm clinical trials with time‐to‐event primary endpoints using Weibull distribution.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 610, doi. 10.1002/pst.2097

By:

Waleed, Muhammad;
He, Jianghua;
Phadnis, Milind A.

Publication type:

Article

Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 675, doi. 10.1002/pst.2100

By:

Lasch, Florian;
Guizzaro, Lorenzo;
Aguirre Dávila, Lukas;
Müller‐Vahl, Kirsten;
Koch, Armin

Publication type:

Article

Joint hypothesis testing of the area under the receiver operating characteristic curve and the Youden index.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 657, doi. 10.1002/pst.2099

By:

Yin, Jingjing;
Mutiso, Fedelis;
Tian, Lili

Publication type:

Article

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 551, doi. 10.1002/pst.2093

By:

Best, Nicky;
Price, Robert G.;
Pouliquen, Isabelle J.;
Keene, Oliver N.

Publication type:

Article

A Bayesian adaptive design for biosimilar trials with time‐to‐event endpoint.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 597, doi. 10.1002/pst.2096

By:

Belay, Sheferaw Y.;
Mu, Rongji;
Xu, Jin

Publication type:

Article

Designing and analyzing clinical trials for personalized medicine via Bayesian models.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 573, doi. 10.1002/pst.2095

By:

Zhang, Chuanwu;
Mayo, Matthew S.;
Wick, Jo A.;
Gajewski, Byron J.

Publication type:

Article

A natural lead‐in approach to response‐adaptive allocation for continuous outcomes.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 563, doi. 10.1002/pst.2094

By:

Donahue, Erin;
Sabo, Roy T.

Publication type:

Article

Response‐adaptive trial designs with accelerated Thompson sampling.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 645, doi. 10.1002/pst.2098

By:

Wang, Jixian

Publication type:

Article

A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 528, doi. 10.1002/pst.2092

By:

Yu, Chang;
Huang, Xiang;
Nian, Hui;
He, Philip

Publication type:

Article

Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 512, doi. 10.1002/pst.2091

By:

Magirr, Dominic

Publication type:

Article

Sample size calculations for single‐arm survival studies using transformations of the Kaplan–Meier estimator.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 499, doi. 10.1002/pst.2090

By:

Nagashima, Kengo;
Noma, Hisashi;
Sato, Yasunori;
Gosho, Masahiko

Publication type:

Article

A confidence function‐based posterior probability design for phase II cancer trials.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 485, doi. 10.1002/pst.2089

By:

Shan, Minghua

Publication type:

Article

A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 462, doi. 10.1002/pst.2088

By:

Bennett, Maxine;
White, Simon;
Best, Nicky;
Mander, Adrian

Publication type:

Article

A class of goodness‐of‐fit test for the additive hazards model with case‐cohort data.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 451, doi. 10.1002/pst.2087

By:

Cao, Yongxiu;
Yu, Jichang

Publication type:

Article

Adjusting win statistics for dependent censoring.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 440, doi. 10.1002/pst.2086

By:

Dong, Gaohong;
Huang, Bo;
Wang, Duolao;
Verbeeck, Johan;
Wang, Jiuzhou;
Hoaglin, David C.

Publication type:

Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 419, doi. 10.1002/pst.2035
Publication type:: Article

Bayesian optimization design for dose‐finding based on toxicity and efficacy outcomes in phase I/II clinical trials.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 3, p. 422, doi. 10.1002/pst.2085

By:

Takahashi, Ami;
Suzuki, Taiji

Publication type:

Article